Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Merck
Colorcon
Covington
Moodys
UBS
Cantor Fitzgerald
Chubb
Queensland Health

Generated: August 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203505

« Back to Dashboard

NDA 203505 describes OSPHENA, which is a drug marketed by Duchesnay and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the OSPHENA profile page.

The generic ingredient in OSPHENA is ospemifene. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ospemifene profile page.
Summary for 203505
Tradename:OSPHENA
Applicant:Duchesnay
Ingredient:ospemifene
Patents:8
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 203505
Generic Entry Date for 203505*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 203505
Suppliers and Packaging for NDA: 203505
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OSPHENA ospemifene TABLET;ORAL 203505 NDA Shionogi Inc. 59630-580 N 59630-580-18
OSPHENA ospemifene TABLET;ORAL 203505 NDA Shionogi Inc. 59630-580 N 59630-580-55

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength60MG
Approval Date:Feb 26, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 26, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Jul 21, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
Patent:➤ Try a Free TrialPatent Expiration:Aug 11, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Johnson and Johnson
Fuji
US Department of Justice
US Army
Mallinckrodt
Argus Health
Teva
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.